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Abstract
Background/purpose One to three per cent of the world’s population has hepatitis C virus (HCV) infection, which is not
only a major cause of liver disease and cancer but also associated with an increased risk of atherosclerosis, despite an
ostensibly favourable lipid profile. Autoantibodies are frequent in HCV infection and emerging evidence shows that
autoantibodies could be valuable for cardiovascular disease (CVD) risk stratification. This study investigated a novel
independent biomarker of CVD, autoantibodies to apolipoprotein A-1 (anti-apoA-1 IgG) and lipids in patients with chronic
HCV before, during and after direct-acting anti-viral (DAA) therapy.
Methods Eighty-nine blinded serum samples from 27 patients with advanced chronic HCV were assayed for lipids and
anti-apoA-1 IgG by ELISA.
Results Pre-treatment HCV viral load correlated with high-density lipoprotein cholesterol (HDL-C, r = 0.417; p = 0.042)
and negatively with apolipoprotein (apo)B (r = - 0.497; p = 0.013) and markers of CVD risk, the apoB/apoA-1 ratio
(r = - 0.490; p = 0.015) and triglyceride level (TG)/HDL-C ratio (r = - 0.450; p = 0.031). Fourteen (52%) of 27
patients had detectable anti-apoA-1 IgG autoantibodies pre-treatment; only two became undetectable with virological cure.
Autoantibody-positive sera had lower apoA-1 (p = 0.012), HDL-C (p = 0.009) and total cholesterol (p = 0.006) levels.
Conclusions This is the first report of the presence of an emerging biomarker for atherosclerosis, anti-apoA-1 IgG, in some
patients with HCV infection. It may be induced by apoA-1 on the surface of HCV lipoviral particles. The autoantibodies
inversely correlate with apoA-1 and HDL levels and may render HDL dysfunctional. Whether these hypothesis-generating
findings have clinical implications in HCV patients requires further study.
Keywords Hepatitis C virus  Autoimmunity  Atherosclerosis  Cardiovascular risk  Apolipoprotein A-1
Introduction
It is estimated that 1–3% of the world’s population has
chronic hepatitis C virus (HCV) infection, which is a major
cause of liver disease and liver cancer. HCV-infected
patients also have increased rates of atherosclerosis, which
leads to a higher risk of cardiovascular [1] and cere-
brovascular morbidity and mortality [2]. The Framingham
Risk Score (FRS) may underestimate coronary heart dis-
ease (CHD) risk in both HCV mono-infected and HIV/
& Margaret F. Bassendine
m.bassendine@imperial.ac.uk
1 Faculty of Health and Life Sciences, Northumbria University,
Newcastle upon Tyne, UK
2 Institute of Cellular Medicine, Newcastle University,
Newcastle upon Tyne, UK
3 Division of Laboratory Medicine, Department of Genetics
and Laboratory Medicine, Geneva University Hospitals,
Geneva, Switzerland
4 The Liver Unit, Blizard Institute, Queen Mary University of
London, London, UK
5 Department of Clinical Biochemistry, Newcastle upon Tyne
Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK
6 Department of Hepatology and Gastroenterology, Imperial
College London, 10th Floor QEQM Wing, St. Mary’s
Hospital Campus, South Wharf Street, London W2 1NY, UK
123
Hepatology International
https://doi.org/10.1007/s12072-018-9842-5(0123456789().,-volV)(0123456789().,-volV)
HCV co-infected persons [3] as cholesterol levels are lower
in patients with chronic hepatitis C [4]. Autoantibodies are
frequent in HCV infection and emerging evidence shows
that autoantibodies could be of valuable help for cardio-
vascular risk stratification [5]. Autoantibodies against
apolipoprotein A-1 (anti-apoA-1 IgG) have emerged as an
independent biomarker for cardiovascular disease and
mortality in several populations [6, 7]. These autoanti-
bodies may be mediators of plaque vulnerability [8]. In
rheumatoid arthritis anti-apoA-1 IgG improves the Fram-
ingham 10-year cardiovascular (CV) risk score [9]. The
presence of anti-apoA-1 autoantibodies is also a risk bio-
marker for cardiovascular disease in type 2 diabetes mel-
litus [10], which is increased in HCV infection [11].
Apolipoprotein A-1 (apoA-1), the major structural pro-
tein of high-density lipoprotein (HDL), interacts with
Scavenger receptor class B type 1 (SR-B1), which is the
endogenous receptor for HDLs in the liver. SR-B1 is
known to be involved in HCV entry and HDLs facilitate
viral entry [12]. In vitro small molecule scavenger receptor
BI antagonists are potent HCV entry inhibitors [13].
Another in vitro study showed that specific siRNA-medi-
ated downregulation of apoA-I led to a reduction in both
HCV RNA and viral particle levels indicating hepatitis C
virus production requires apoA-1 [14]. ApoA-1 has been
shown to be incorporated into HCV particles and exposed
on the surface of virions [15], leading to the suggestion that
HCV has developed an advantageous strategy to hijack the
physiological interaction of HDL with SR-BI. This ultra-
structural study confirmed that HCV particles incorporate
apoB and apoE and showed that host apolipoproteins were
more readily accessible to antibody labelling than HCV
envelope glycoproteins. Infectious hepatitis C virions
associated with these host lipoproteins are termed lipoviral
particles (LVP). The lipoprotein components of LVP not
only play key roles in viral attachment and entry, but also
reduce the sensitivity of HCV to neutralising antibodies
and mask viral epitopes [16, 17].
This study investigated serum lipids and the novel
independent biomarker of CVD, autoantibodies to
apolipoprotein A-1 (anti-apoA-1 IgG) in patients with
chronic HCV before, during and after direct-acting anti-
viral (DAA) therapy.
Materials and methods
Ethics
Ethical approval was obtained from City Road and
Hampstead (formerly Moorfields and Whittington)
Research Ethics Committee for serial blood sampling of
patients with chronic hepatitis C virus infection undergoing
antiviral therapy.
Patients
Eighty-nine non-fasting serum samples from 27 patients
with advanced chronic HCV [n = 15 genotype (GT) 1, 2
with mixed cryoglobulinemia (MC) and n = 12 GT3, 2
with MC (Table 1)] who had received treatment with
sofosbuvir-based direct-acting antiviral (DAA) therapy
were assayed for anti-apoA-1 IgG and serum lipids. In
HCV GT1 patients sofosbuvir was combined with ledi-
pasvir (? ribavirin in 10/15 and ? pegylated IFN in 1/15)
and in HCV GT3 patients it was combined with daclatasvir
in 11/12 and with ribavirin and pegylated IFN in 1/12.
Twenty of 27 of the patients had established cirrhosis
and 2 of these had type 2 diabetes mellitus. Twenty-four of
27 were non-responders to previous course(s) of interferon
(IFN)-based anti-viral therapy. The samples were obtained
before, during and after treatment; 76/89 serum samples
were from 20/27 patients (between 3 and 6 samples per
patient) and 12/89 serum samples were from 6/27 patients
(2 samples per patient); the remaining 1/89 serum sample
was obtained pre-treatment but there was insufficient
serum available at later time points for analysis (see Fig. 1
for serial samples in each patient). All 89 samples were
labelled randomly and assayed ‘blind’ to patient source and
the results of DAA therapy.
Lipid profiles
Total cholesterol, triglyceride (TG) and HDL-cholesterol
(HDL-C) levels were measured by automated enzymatic
methods and low-density lipoprotein (LDL) cholesterol
was estimated indirectly with the Friedewald equation
[(LDL-cholesterol) = (total cholesterol) – (HDL-choles-
terol) – (TG)/2.2]. Apolipoproteins A-I and B were mea-
sured by automated immunoturbidometric methods on a
Roche Cobas Modular c702 analyser (Roche Diagnostics,
Lewes, UK).
Anti-apoA-1 IgG ELISA
Serum samples were assayed for anti-apoA-1 antibody
levels as previously described [6, 8, 18, 19]. Briefly, Maxi-
Sorb plates (Nunc) were coated with purified, human-
derived delipidated apoA-1 (20 lg/ml; 50 ll/well) for 1 h
at 37 C. After three washes with phosphate-buffered sal-
ine (PBS)/2% bovine serum albumin (BSA; 100 ll/well),
all wells were blocked for 1 h with 2% BSA at 37 C.
Samples were diluted 1:50 in PBS/2% BSA and incubated
for 60 min. Additional patient samples at the same dilution
were also added to an uncoated well to assess individual
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nonspecific binding. After six further washes, 50 ll/well of
signal antibody (alkaline phosphatase-conjugated anti-hu-
man IgG; Sigma-Aldrich) diluted 1:1000 in PBS/2% BSA
solution was incubated for 1 h at 37 C. After six more
washes (150 ll/well) with PBS/2% BSA solution, the
phosphatase substrate p-nitrophenyl phosphate disodium
(50 ll/well; Sigma-Aldrich) dissolved in diethanolamine
buffer (pH 9.8) was added. Each sample was tested in
duplicate and absorbance, determined as the optical density
at 405 nm (OD405 nm), was determined after 20 min of
incubation at 37 C (VersaMax, Molecular Devices). The
corresponding nonspecific binding value was subtracted
from the mean absorbance value for each sample. The
positivity cutoff was predefined as previously validated and
set at an OD value of 0.6 and 37% of the positive control
value as described earlier [18–20]. At the cutoff level, the
intra- and inter-assay coefficients of variation were shown
to be 16% (n = 10) and 12% (n = 8), respectively [20].
Statistical analyses
Statistical analysis was performed with the use of Minitab
17 (Minitab Ltd, Coventry, UK) and GraphPad Prism 7
(GraphPad, La Jolla, USA). The distribution of continuous
data variables was assessed by normality tests. Normally
distributed continuous variables were reported as means ±
standard deviations and compared between groups using
two-sample t tests. Non-parametrically distributed vari-
ables were reported as median and interquartile ranges and
compared between groups using Kruskal-Wallis tests. The
correlation between two continuous variables was assessed
using either Pearson’s correlation coefficient test for
parametric data or Spearman’s rank correlation test for
non-parametric ranked data variables. The strength of the
association (R2) between groups was assessed with
regression analysis. For all analyses p\ 0.05 was consid-
ered significant.
Results
Blinded serial serum samples (n = 89) from 27 patients
with chronic hepatitis C infection undergoing DAA therapy
were assayed for viral load, lipids and anti-apoA-1 IgG
(AAA1). The clinical characteristics of the patients at
baseline and week 12 are summarised in Table 1. There
Table 1 Serum lipids in 27 patients with advanced chronic hepatitis C infection before and at the end (week 12) of direct-acting antiviral therapy
Characteristics HCV genotype 1, n = 15 HCV genotype 3, n = 12
Baseline Week 12 p value* Baseline Week 12 p value*
Sex, n (M/F) 11/4 – 7/5 –
Age (yr), median (range) 62 (48–74) – 56 (36–65) –
HCV RNA log10 (IU/ml), mean ± SD 5.80 ± 0.82 0 – 5.33 ± 0.74 0 –
Total cholesterol (mmol/l), median (IQR) 4.25 (1.75) 4.30 (1.15) 0.662 4.10 (1.18) 4.40 (1.90) 0.652
LDL-C (mmol/l), mean ± SD 2.27 ± 0.83 2.10 (0.74) 0.666 2.37 ± 0.84 2.48 ± 0.76 0.762
Apolipoprotein B (g/l), median (IQR) 0.79 (0.49) 0.76 (0.24) 0.512 0.87 (0.47) 0.86 (0.42) 0.722
HDL-C (mmol/l), mean ± SD 1.44 ± 0.48 1.56 ± 0.46 0.511 1.26 ± 0.40 1.36 ± 0.44 0.603
Apoprotein A1 (g/l), mean ± SD 1.63 ± 0.29 1.63 ± 0.43 0.972 1.38 ± 0.30 1.50 ± 0.39 0.432
Triglyceride (mmol/l), median (IQR) 1.20 (1.40) 1.10 (0.90) 0.456 1.25 (0.55) 1.50 (0.90) 0.773
ApoB/apoA1 ratio, median (IQR) 0.46 (0.39) 0.46 (0.35) 0.593 0.62 (0.24) 0.51 (0.25) 0.657
TG/HDL-C ratio, median (IQR) 0.92 (1.01) 0.69 (0.89) 0.505 1.08 (0.99) 1.00 (0.82) 0.653
TC/HDL-C ratio, median (IQR) 2.71 (2.70) 2.63 (1.92) 0.437 3.23 (1.66) 3.39 (1.63) 0.838
Anti-apoA1 antibodiesa, median (IQR) 34.20 (27.70) 37.30 (27.23) 0.565 45.60 (32.40) 37.00 (32.43) 0.510
ApoB/apoA1, apolipoprotein B/apolipoprotein A1 ratio
Parametric variables shown as the mean plus/minus standard deviation. Non-parametric variables shown as the median and the interquartile range
IQR interquartile range, SD standard deviation; TC/HDL-C total cholesterol/high-density lipoprotein cholesterol, TG/HDL-C triglyceride/high-
density lipoprotein cholesterol
*p values presented are for the comparison between variables at baseline and week 12. p\ 0.05 was considered significant
p value calculated using the non-parametric Kruskal-Wallis test
p value calculated using the parametric t test
aThe anti-ApoA-1 antibody positivity cutoff was predefined at 37%, which corresponded to an OD405 nm of 0.6 as previously validated and
described (18–20)
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was no significant difference in the serum lipid concen-
trations at week 0 and 12 of DAA therapy, when all 27
patients had a virological response (undetectable HCV
RNA).
Pre-treatment (week 0) HCV viral load positively cor-
related with high-density lipoprotein cholesterol (HDL-C,
r = 0.417; p = 0.042) and negatively with apoB
(r = - 0.497; p = 0.013) and LDL-C (r = - 0.494;
p = 0.017). Ratios associated with increased cardiovascu-
lar disease risk were also negatively correlated with the
HCV RNA:apoB/apoA-1 ratio (r = - 0.490; p = 0.015),
TG/HDL-C ratio (r = - 0.450; p = 0.031) and total
cholesterol/HDL-C ratio (r = - 0.450; p = 0.027).
Fourteen of the 27 (52%) patients with chronic HCV (6
GT1, 8 GT3) were found to be seropositive for AAA1
antibodies at baseline prior to receiving DAA therapy.
Twelve patients were positive for AAA1 antibodies at the
end of DAA therapy at week 12. Longitudinal AAA1
analysis before, during and after response to DAA treat-
ment showed that overall 41 (46%) out of 89 serum sam-
ples were positive for AAA1 IgG antibodies. Ten (71%) of
the 14 patients were consistently positive for ApoA-1 IgG,
Fig. 1 Autoantibody to
apolipoprotein A-1 IgG ELISA
reading (cutoff 37%) in 27
patients with advanced chronic
HCV before, during and after
direct-acting anti-viral therapy,
commenced at week 0. By week
12 all patients responded to
antiviral treatment and were
HCV RNA negative. a Results
in HCV genotype 1 patients,
2/15 relapsed after end of
therapy; b results in HCV
genotype 3 patients, 1/12
relapsed. Closed black circles
show autoantibody-positive
patients at week 0, open circles
show autoantibody negative
patients at week 0, the broken
dashed black line shows patients
that changed from seropositive
to seronegative and vice versa
during sampling. Error bars
show the standard deviation
between replicate values. The
thick dashed grey line indicates
a positive AAA1 IgG response
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five (83%) out of the six patients with HCV genotype 1
infection (Fig. 1a) and five (63%) out of the eight patients
with HCV genotype 3 infection (Fig. 1b). A further two
HCV GT3 patients who were positive for AAA1 antibodies
by ELISA became seronegative following virological cure.
Two GT1 patients were intermittently AAA1 seropositive
and then returned to seronegative. Furthermore, when
comparing the AAA1 antibody levels in the 89 serum
samples and stratifying according to the two HCV geno-
types there was a significant difference in the overall levels
of serum AAA1 autoantibodies between GT1 and GT3
patients (Fig. 2, p = 0.019).
Anti-apoA-1 IgG was found in two of four patients with
mixed cryoglobulinemia (MC). To confirm the specificity
of binding, the apoA-1 immunoreactivity was further
analysed in four random HCV serum samples; it was
shown to be specifically inhibited with peptide F3L1 but
not with a scrambled peptide as previously described [20].
Of the 89 serial serum samples evaluated for AAA1
antibodies and lipids, 41 were identified as AAA1 IgG
positive and the remaining 48 were seronegative for AAA1
antibodies. A comparison of the lipoprotein characteristics
of the seropositive and -negative samples is summarised in
Table 2. Eighteen of the 41 anti-apoA-1 IgG-positive sera
had detectable HCV RNA (5.04 ± 1.3 log10 IU/ml). In the
41 AAA1-positive sera, Spearman correlation analysis
using ranked variables showed that the magnitude of the
autoantibody response inversely correlated with cholesterol
(p = 0.005), HDL-C (p = 0.025), apoA-1 (p = 0.014) and
apoB (p = 0.040). Linear regression analyses showed that
the magnitude of the AAA1 autoantibody response was a
significant negative predictor of cholesterol concentration
(Fig. 3, R2 = 10.24%; p = 0.005).
As anti-apoA-1 is a novel biomarker of CVD, we
determined whether there is any correlation of traditional
lipid ratios associated with increased CVD risk with the
presence of anti-apoA-1 IgG. At pre-treatment there was no
correlation of anti-apoA-1 IgG with the apoB/apoA-1 ratio
(r = - 0.236; p = 0.268), TG/HDL-C ratio (r = 0.148;
p = 0.499) and total cholesterol/HDL-C ratio
(r = - 0.151; p = 0.481). Overall, the magnitude of the
AAA1 response showed no correlation with these lipid
CVD risk ratios, as shown in Fig. 4.
Discussion
Epidemiological studies have shown HCV is associated
with an increased risk of cardiovascular and cerebrovas-
cular mortality as well as peripheral arterial disease (re-
viewed in [2]). HCV is associated with an ostensibly
favourable lipid profile with an accompanying low classi-
cal risk score for atherosclerosis, so it is unclear how best
to assess cardiovascular risk [21]. Anti-ApoA-1 IgG is an
emerging prognostic cardiovascular marker [22] and in this
‘proof of concept’ study we have shown for the first time
that around half of patients with chronic HCV have these
autoantibodies.
Previous studies using the same ELISA to detect serum
anti-apoA-1 IgG have found it in a proportion of healthy
subjects (0–6.5%) without CVD or autoimmune disease
(reviewed in [22] [23]). In a large population-based study
(n = 6649 subjects) the prevalence of anti-apoA-1 IgG in
the general population was 19.9 % and was significantly
associated with CVD [odds ratio 1.34, p = 0.018], inde-
pendently of established CV risk factors [24]. In this large
population based study anti-apoA-1 IgG levels indepen-
dently predicted all-cause mortality and were found to be
linked to FCRL3, a susceptibility gene for numerous
autoimmune diseases [25], which encodes a member of the
immunoglobulin receptor superfamily.
The presence of anti-apoA-1 IgG in the serum of around
half of these patients with chronic HCV is similar or higher
than has been reported in other diseases [20]. For example,
in patients with periodontitis, where it is a biomarker of
atherosclerosis burden, the prevalence of anti-apoA-1 IgG
was found to be 23.8% compared to 6.5% in age- and sex-
matched controls (p = 0.009) [23]. In patients with
rheumatoid arthritis anti-apoA-1 IgG positivity was 17%
and was associated with a higher incidence of major car-
diovascular events [9]. In a recent study in type 2 diabetes
the incidence of autoantibodies to apoA-1 was 37.5% in
patients with cardiovascular disease (CVD) and patients
who were autoantibody positive showed 5.7 times
increased CVD risk [10].
Fig. 2 Level of serum autoantibody to apolipoprotein A-1 IgG by
ELISA [cutoff 37% and shown by the broken red line] in advanced
chronic HCV according to HCV genotype. HCV GT1 (n = 52
samples, 31 HCV RNA negative and 21 with detectable HCV RNA).
HCV GT3 (n = 37 samples, 22 HCV RNA negative and 15 with
detectable HCV RNA). Higher AAA1 antibody levels were found in
HCV GT3 patients compared to HCV GT1 patients (38.2 vs. 33.2%;
p = 0.019)
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Anti-apoA-I IgG is thus recognised as an independent
predictor of poor cardiovascular outcome in several dif-
ferent populations at risk for CVD with and without con-
comitant autoimmune disease and provides incremental
prognostic information over traditional risk factors for
CVD [20]. It would be of considerable interest if this novel
biomarker is predictive of atherosclerosis and atheroscle-
rotic plaque vulnerability in the setting of chronic HCV
where assessment of CV risk remains an unmet clinical
need.
In this study we found higher serum levels of anti-apoA-
1 IgG in patients with HCV genotype 3 infection, which
needs confirmation in a larger cohort. HCV GT3 is asso-
ciated with a higher risk of early death and liver-related
clinical events [26] and we have previously reported
genotype-specific differences in regulation of lipoproteins
[27]. Anti-ApoA-1 IgG serum levels have been found to
predict worse post-stroke outcomes [28] and HCV is
associated with increased cerebrovascular morbidity and
mortality [2].
Generally, HDL and its principal protein component,
apoA-1, are considered to be atheroprotective. We con-
firmed that AAA1 antibody-positive sera had significantly
lower serum levels of both HDL and apoA-1, implying a
possible role in atherogenesis through HDL dysfunction.
We also confirmed pre-treatment that the hepatitis C viral
load correlated negatively with LDL, the ‘bad’ cholesterol,
and with other ‘classic’ CVD risk ratios. For example, the
ApoB/apoA-1 ratio has been proposed as a simple, accurate
Table 2 Comparison of characteristics between anti-apolipoprotein-A1 (AAA1) IgG-positive samples and AAA1 negative samples
Characteristic Anti-apolipoprotein Al seropositive, n = 41 Anti-apolipoprotein Al seronegative,
n = 48
p value *
HCV RNA log10 (IU/ml), mean ± SD 2.27 ± 2.67 1.93 ± 2.68 0.552
Total cholesterol (mmol/l), median 3.90 (1.10) 4.70 (1.18) 0.006
(IQR) LDL-C (mmol/l), median (IQR) 2.16 (1.55) 2.32 (1.27) 0.308
Apolipoprotein B (g/l), median (IQR) 0.79 (0.48) 0.85 (0.41) 0.063
HDL-C (mmol/l), mean ± SD 1.25 ± 0.39 1.54 ± 0.64 0.009
Apolipoprotein A1 (g/l), mean ± SD 1.40 ± 0.33 1.60 ± 0.42 0.012
Triglyceride (mmol/l), median (IQR) 1.30 (0.65) 1.20 (0.93) 0.341
ApoB/apoA1 ratio, median (IQR) 0.52 (0.37) 0.50 (0.35) 0.557
TG/HDL-C ratio, median (IQR) 1.00 (1.00) 0.85 (1.00) 0.105
TC/HDL-C ratio, median (IQR) 3.33 (2.17) 3.11 (2.96) 0.873
Anti-apoA1 antibodiesa, median (IQR) 48.00 (14.30) 21.50 (8.84) < 0.001
ApoB/apoA1, apolipoprotein B/apolipoprotein A1 ratio; HDL-C, high-density lipoprotein cholesterol
Parametric variables shown as the mean ± standard deviation. Non-parametric variables shown as the median and interquartile range
LDL-C low-density lipoprotein cholesterol, IQR interquartile range, OD optical density, SD standard deviation, TC/HDL-C total cholesterol/high-
density lipoprotein cholesterol, TG/HDL-C triglyceride/high-density lipoprotein cholesterol
*p values presented are for the variable comparison between AAA1 seropositive samples and AAA1 seronegative samples. p\ 0.05 was
considered significant
p value calculated using the parametric t test
p value calculated using the non-parametric Kruskal-Wallis test
aThe anti-ApoA-1 antibody positivity cutoff was predefined at 37%, which corresponded to an OD405 nm of 0.6 as previously validated and
described (18–20)
Fig. 3 IgG autoantibody response to apoA-1 is associated with
cholesterol concentration. Correlation analysis showed an inverse
relationship between AAA1 autoantibody responses and cholesterol
concentration (r = - 0.32; p = 0.005). Linear regression analysis
showed that the magnitude of the AAA1 autoantibody response was a
significant negative predictor of cholesterol concentration
(R2 = 10.24; p = 0.005). Open circled samples were AAA1 IgG-
negative samples and closed black circles were AAA1 IgG-positive
samples
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risk factor for cardiovascular disease [29]—the lower the
apoB/apoA-I ratio, the lower is the risk. However, we
found the lower the ratio, the higher the viral load pre-
treatment, so this simple ‘marker’ may underestimate CVD
risk in HCV infection. Overall, there was no significant
association of traditional lipid CVD risk factors with anti-
apoA-1 IgG in this cohort, which reflects not only the
profound effect of HCV on lipid parameters but also the
effect of this autoantibody on HDL-C and cholesterol
levels.
As expected [4], these patients had low/normal serum
cholesterol levels and we found no significant rise at the end
of DAA treatment (EOT, week 12). However, patients with
chronic HCV whose sera were anti-apoA-1 IgG positive had
significantly lower total serum cholesterol levels, suggesting
that these autoantibodies are modulating lipid metabolism in
chronic hepatitis C. The concept of HCV hijacking the
machinery responsible for controlling lipid metabolism to
improve viral fitness has recently been supported by a study
of the effect of direct-acting anti-viral therapy on the
peripheral and hepatic lipid metabolism [30]. Rapid changes
in the serum lipoprotein particle concentration during DAA
treatment were observed including an increase in LDL early
in therapy, reflecting a shift in lipid metabolism in the setting
of inhibition of HCV replication and implicating a direct
viral effect on serum lipoprotein concentrations. This study
also found that rapid changes in the apoB/apoA-1 ratio
during DAA therapy were not sustained at EOT [30], similar
to our findings at week 12 of DAA therapy.
In contrast to these dynamic changes in serum lipopro-
tein composition and concentration during DAA therapy,
we found that the presence or absence of autoantibody to
apoA-1 remained largely stable during sofosbuvir-based
antiviral therapy and after virological cure over a short
follow-up period. This is similar to experience in children
with chronic hepatitis C receiving IFN-based anti-viral
therapy where autoantibodies were found to be common at
baseline, during and after treatment [31]. The vast majority
of our patient cohort had received prior IFN-based anti-
viral therapy and IFN may induce autoimmune disorders or
worsen pre-existing autoimmune disorders [32], so it will
be important to establish whether the prevalence of anti-
apoA-1 IgG is similar in untreated HCV infection. Sofos-
buvir plus daclatasvir has recently been shown to be
effective in patients with HCV-associated cryoglobuline-
mia vasculitis with a fall in cryoglobulin levels after
antiviral therapy but an increased number of T-regulatory
cells [33]. It is thus of interest that we found only 2/14
patients with positive anti-apoA-1 IgG pre-treatment
became seronegative with virological cure. It is possible
that the continuing presence of autoantibodies after cure
[31] contributes to the increase in regulatory T cells, which
have a role in the suppression of autoimmune responses.
Previous work has shown that the anti-apoA-I autoan-
tibody response is strongly biased towards the C-terminal
alpha-helix of the protein [20], which plays an important
role in lipid binding. These autoantibodies may thus
modulate binding of hepatitis C LVP to SR-B1 as it has
been shown that various lipoprotein receptors redundantly
Fig. 4 IgG autoantibody response to apoA-1 is not associated with
traditional lipid cardiovascular risk factors; a shows no significant
relationship with the proatherogenic:antiatherogenic ratio apoB/
apoA-1, b shows no significant relationship with TG/HDL-C and
c shows no significant relationship with the total cholesterol/HDL-C
ratio. Open circled samples were AAA1 IgG-negative samples and
closed black circles were AAA1 IgG-positive samples
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participate in HCV entry, in a manner dependent on the
lipoproteins associated with HCV particles [34]. ApoA-1 is
exposed on the surface of infectious HCV lipoviral parti-
cles [15] and these autoantibodies may be exerting anti-
viral activity, similar to downregulation of apoA-1 [14].
The link between HCV infection and atherosclerosis is
intriguing and pathogenic mechanisms remain elusive as
HCV has such a profound effect on lipid components of the
Framingham Risk Score and traditional lipid biomarkers of
CVD. While our results should be interpreted with caution
given the small sample size of the study, we suggest that
apoA-1 on the surface of HCV lipoviral particles may lead to
the development of autoantibodies to this host lipoprotein in
predisposed individuals. It will be important to establish
whether these autoantibodies develop during acute HCV
infection where the titre of IgG antibody to HCV proteins
only rises by the 4th to 6th month after infection [35]. The
high prevalence of these autoantibodies in chronic HCV
infection may be linked to the increased risk of atheroscle-
rosis and associated morbidity and mortality.
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